Skip to main content
. 2021 May 26;184(12):3086–3108. doi: 10.1016/j.cell.2021.05.005

Figure 1.

Figure 1

Timeline of approval of mAbs for all indications (black) and for infectious disease (blue)

Sotrovimab received EUA at the time of publication.